TARO PROVIDES RESULTS FOR QUARTER ENDED JUNE 30, 2019

Hawthorne, NY, August 8, 2019 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2019.

Quarter ended June 30, 2019 Highlights - compared to June 30, 2018

●	Net sales of $161.3 million, increased $6.7 million, or 4.3%, despite a single digit decrease in volumes primarily due to category mix.

●	Gross profit of $101.7 million increased $1.6 million, and as a percentage of net sales was 63.1% compared to 64.7%.

●	Research and development expenses of $13.4 million remained in line with prior year.

●	Selling, marketing, general and administrative expenses of $19.7 million decreased $3.9 million.

●	Operating income of $68.6 million increased $5.4 million and as a percentage of net sales was 42.5% as compared to 40.8%.

●	Interest and other financial income increased $1.8 million to $9.6 million.

●	Foreign Exchange (FX) income of $7.9 million decreased $2.1 million the result of the strengthening of the Canadian dollar vs. the U.S. dollar.

●	Tax expense of $20.4 million increased $6.3 million with the effective tax rate increasing to 23.6% from 17.3%.

●	Net income attributable to Taro was $66.2 million compared to $67.3 million, resulting in diluted earnings per share of $1.72 compared to $1.71.

Cash Flow and Balance Sheet Highlights

●	Cash flow provided by operations was $82.6 million compared to $82.4 million for the three months ended June 30, 2018.

●	As of June 30, 2019, cash, including short-term and long-term marketable securities and bank deposits, increased $77.6 million to $1.431 billion from March 31, 2019.

Mr. Uday Baldota, Taro’s CEO stated, “Operating results of this quarter reflect the impact of many underlying challenges of our industry.  Despite the headwinds, we remain steadfast in our commitment to customers and patients.  We are executing on our strategy and continue to add to our portfolio of high quality products across business and markets.”

- more -

Taro Pharmaceutical Industries Ltd.

Page 2 of 5

The Company recently received two approvals from the U.S. Food and Drug Administration (“FDA”) for Abbreviated New Drug Applications (“ANDAs”); Dapsone Gel, 7.5% and Iloperidone Tablets, 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg.  The Company currently has a total of twenty-six ANDAs awaiting FDA approval, including seven tentative approvals.

On June 20, 2019, the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (“SEC”) for the fiscal year ended March 31, 2019.

************************

The Company cautions that the foregoing financial information is presented on an unaudited basis and is subject to change.

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.  For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

SAFE HARBOR STATEMENT

The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company.  The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2020.  Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained.  Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F.  Forward-looking statements are applicable only as of the date on which they are made.  The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

**Financial Tables Follow**

Page 3 of 5

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(U.S. dollars in thousands, except share data)

May not foot due to rounding.

 SUMMARY CONSOLIDATED BALANCE SHEETS

		June 30,				March 31,
		2019				2019
ASSETS		(unaudited)				(audited)
CURRENT ASSETS:
Cash and cash equivalents		$	632,986			$	567,451
Marketable securities			506,751				481,883
Accounts receivable and other:
Trade, net			213,514				237,945
Corporate tax receivable			9,476				25,969
Other receivables and prepaid expenses			22,645				21,393
Inventories			148,283				148,079
TOTAL CURRENT ASSETS			1,533,655				1,482,720
Long-term deposits and marketable securities			291,544				304,322
Property, plant and equipment, net			205,654				206,242
Deferred income taxes			108,852				110,974
Other assets			32,495				31,068
TOTAL ASSETS		$	2,172,200			$	2,135,326
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables		$	37,210			$	35,060
Other current liabilities			152,023				181,761
TOTAL CURRENT LIABILITIES			189,233				216,821
Deferred taxes and other long-term liabilities			8,122				7,383
TOTAL LIABILITIES			197,355				224,204
Taro shareholders' equity			1,969,201				1,905,536
Non-controlling interest			5,644				5,586
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		$	2,172,200			$	2,135,326

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(U.S. dollars in thousands)

		Three Months Ended June 30,
		2019				2018
Cash flows from operating activities:
Net income		$	66,241			$	67,428
Adjustments required to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			5,071				4,299
Realized gain on sale of marketable securities			—				(7	)
Change in derivative instruments, net			(2,421	)			3,546
Effect of change in exchange rate on inter-company balances, marketable securities and bank deposits			(5,624	)			(28,918	)
Deferred income taxes, net			2,930				1,575
Decrease (increase) in trade receivables, net			24,431				(2,897	)
(Increase) decrease in inventories, net			(205	)			2,653
Decrease in other receivables, income tax receivable, prepaid expenses and other			15,671				52,479
Decrease in trade, income tax, accrued expenses, and other payables			(22,965	)			(17,408	)
Income from marketable securities, net			(525	)			(310	)
Net cash provided by operating activities			82,604				82,440
Cash flows from investing activities:
Purchase of plant, property & equipment, net			(7,969	)			(6,078	)
Investment in other intangible assets			(30	)			(45	)
Proceeds from short-term bank deposits, net			—				51,345
Proceeds from long-term deposits and other assets			—				70,685
Investment in marketable securities, net			(9,070	)			(107,644	)
Net cash (used in) provided by investing activities			(17,069	)			8,263
Cash flows from financing activities:
Purchase of treasury stock			—				(24,655	)
Net cash used in financing activities			—				(24,655	)
Effect of exchange rate changes on cash and cash equivalents			—				(670	)
Increase in cash and cash equivalents			65,535				65,378
Cash and cash equivalents at beginning of period			567,451				576,611
Cash and cash equivalents at end of period		$	632,986			$	641,989
Cash Paid during the year for:
Income taxes		$	10,432			$	36,830
Cash Received during the year for:
Income taxes		$	7,128			$	60,544
Non-cash investing transactions:
Purchase of property, plant and equipment included in accounts payable		$	2,317			$	1,823
Non-cash financing transactions:
Purchase of marketable securities		$	2,436			$	8,629

#####